Small molecule · Inhibitor of Smoothened receptor (SMO) · developed by Sol-Gel Technologies
Patidegib is a topical gel containing a cyclopamine-derived inhibitor that binds the G-protein coupled receptor smoothened (SMO) and blocks Hedgehog pathway signaling, reducing proliferation and survival of tumor cells with overactive Hedgehog signaling. It is applied locally to limit systemic exposure and is studied in basal cell nevus syndrome (Gorlin syndrome).
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT06050122 | Phase 3 | Gorlin Syndrome | Completed | SLGL |
| NCT04308395 | Phase 3 | Basal Cell Nevus Syndrome | Terminated | SLGL |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Basal Cell Nevus SyndromeGorlin Syndrome
Updated Nov 1, 2026. Something wrong or missing? Report it on the SLGL page.
See SLGL's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
SLGL catalysts and pipeline →